TY - JOUR
T1 - Chronic Lymphocytic Leukemia
T2 - Diagnosis and Treatment
AU - Strati, Paolo
AU - Jain, Nitin
AU - O'Brien, Susan
N1 - Publisher Copyright:
© 2018 Mayo Foundation for Medical Education and Research
PY - 2018/5
Y1 - 2018/5
N2 - The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib, idelalisib, and venetoclax, as well as increasingly potent anti-CD20 monoclonal antibodies. In addition, the identification of molecular predictive markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease have allowed optimization of the use of chemoimmunotherapy and targeted therapies and may become standard of care in the future. This review summarizes the diagnosis, prognostication, and treatment of patients with chronic lymphocytic leukemia with emphasis on new prognostic and predictive factors and novel treatment strategies.
AB - The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib, idelalisib, and venetoclax, as well as increasingly potent anti-CD20 monoclonal antibodies. In addition, the identification of molecular predictive markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease have allowed optimization of the use of chemoimmunotherapy and targeted therapies and may become standard of care in the future. This review summarizes the diagnosis, prognostication, and treatment of patients with chronic lymphocytic leukemia with emphasis on new prognostic and predictive factors and novel treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=85046366211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046366211&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.03.002
DO - 10.1016/j.mayocp.2018.03.002
M3 - Review article
C2 - 29728204
AN - SCOPUS:85046366211
SN - 0025-6196
VL - 93
SP - 651
EP - 664
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 5
ER -